Pfizer Quarterly Cash Flow Statement
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:01 PM ET · Delayed 15 min
Pfizer free cash flow
In the quarter ended Jun 28, 2026, Pfizer generated $835.0 million of operating cash flow and spent $533.0 million on capital expenditures. That left free cash flow of $302.0 million, a free-cash-flow margin of 2.0% of revenue. Pfizer returned $2.45 billion to shareholders through dividends, equal to 812% of free cash flow.
Free cash flow covered dividend payments 0.1 times.
Summary generated from market data by MetaCap's automated system. Methodology
Pfizer cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-28 | Q1 20262026-03-29 | Q4 20252025-12-31 | Q3 20252025-09-28 | Q2 20252025-06-29 | Q1 20252025-03-30 | Q4 20242024-12-31 | Q3 20242024-09-29 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-10-01 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -237.00M | 2.70B | -1.64B | 3.55B | 2.93B | 2.97B | 418.00M | 4.47B | 48.00M | 3.12B | -3.36B | -2.38B |
| Net Income growth (YoY) | -108.09% | -9.32% | -492.34% | -20.63% | +6000.00% | -4.80% | — | — | -97.95% | -43.79% | -167.16% | -127.55% |
| Depreciation & Amortization | 1.62B | 1.61B | 1.69B | 1.66B | 1.63B | 1.62B | 1.79B | 1.75B | 1.73B | 1.74B | 1.67B | 1.56B |
| Stock-Based Compensation | 249.00M | 272.00M | 225.00M | 201.00M | 203.00M | 170.00M | 177.00M | 274.00M | 206.00M | 220.00M | 121.00M | 151.00M |
| Change in Working Capital | -1.82B | -1.73B | — | -36.00M | -4.99B | -1.92B | — | 879.00M | -3.54B | -3.34B | 31.00M | -1.20B |
| Operating Cash Flow | 835.00M | 2.62B | 5.35B | 4.60B | -582.00M | 2.33B | 6.72B | 6.71B | -1.78B | 1.09B | 5.24B | 3.46B |
| Capital Expenditures | -533.00M | -436.00M | -845.00M | -602.00M | -618.00M | -564.00M | -917.00M | -651.00M | -637.00M | -704.00M | -1.04B | -810.00M |
| Investing Cash Flow | 2.11B | 785.00M | -6.15B | -2.43B | 3.95B | 3.27B | -1.62B | -2.06B | 4.60B | 1.73B | -11.00B | 888.00M |
| Dividends Paid | -2.45B | -2.44B | -2.44B | -2.44B | -2.44B | -2.44B | -2.38B | -2.38B | -2.38B | -2.37B | -2.31B | -2.31B |
| Share Repurchases | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Issued | — | — | 5.99B | 0 | — | — | 0 | 0 | — | — | 0 | 0 |
| Debt Repaid | — | — | -3.01B | 0 | -3.75B | 0 | 0 | 0 | -1.00B | -1.25B | 0 | -1.30B |
| Financing Cash Flow | -3.66B | -2.86B | 596.00M | -2.48B | -3.20B | -5.23B | -5.11B | -4.64B | -2.46B | -4.93B | 5.44B | -3.78B |
| Net Change in Cash | -727.00M | 563.00M | -196.00M | -301.00M | 213.00M | 375.00M | -45.00M | 29.00M | 343.00M | -2.14B | -316.00M | 535.00M |
| Free Cash Flow | 302.00M | 2.18B | 4.50B | 4.00B | -1.20B | 1.77B | 5.80B | 6.06B | -2.42B | 386.00M | 4.20B | 2.65B |
This table shows 12 quarterly periods of Pfizer's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PFE's reporting calendar. What is a cash flow statement?